Per the brand's FAQ, this includes a review of your profile to ensure GLP-1s are "safe and right for you." The provider makes the independent clinical decision about whether to prescribe, at what dose, and with what monitoring plan
10.3390/brainsci11070831 [DOI] [PMC free article] [PubMed] [Google Scholar] 40.Kindel TL, Wang AY, Wadhwa A, Schulman AR, Sharaiha RZ, Kroh M, et al
Glucagon-like peptide-1 receptor agonists for type 2 diabetes: a clinical update of safety and efficacy
Does PlexusDx genetic testing help optimize my semaglutide dosing schedule
Abstract Background: Parkinsons disease (PD) is a multifactorial, progressive neurodegenerative disorder that primarily affects dopaminergic neurons in the substantia nigra
In animal trials, it avoided the muscle loss side effect of GLP-1 drugs